(NASDAQ: ALGS) Aligos Therapeutics's forecast annual revenue growth rate of 213.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Aligos Therapeutics's revenue in 2025 is $3,270,000.On average, 2 Wall Street analysts forecast ALGS's revenue for 2025 to be $13,177,396, with the lowest ALGS revenue forecast at $1,901,703, and the highest ALGS revenue forecast at $24,459,204. On average, 1 Wall Street analysts forecast ALGS's revenue for 2026 to be $24,459,204, with the lowest ALGS revenue forecast at $24,459,204, and the highest ALGS revenue forecast at $24,459,204.
In 2028, ALGS is forecast to generate $1,461,480,243 in revenue, with the lowest revenue forecast at $1,461,480,243 and the highest revenue forecast at $1,461,480,243.